The Latest Cardiac and Vascular News
TIANJIN, China, Oct. 27, 2021 /PRNewswire/ — SINOMED, a leading international medical device company, announced that the clinical trial results for its HT Supreme® Drug-Eluting Stent (DES) System has been published in Circulation. The article described results from the PIONEER III trial where investigators demonstrated equivalence in safety and effectiveness between the […]
TIANJIN, China, Aug. 17, 2021 /PRNewswire/ — SINOMED, a leading international medical device company, announced the first commercial implantation of the HT Supreme® Drug-Eluting Stent (DES) at University Hospital Galway in partnership with the National University of Ireland Galway (NUI Galway), marking the start of the European launch. The procedure was successfully performed by […]
TIANJIN, China, July 5, 2021 /PRNewswire/ — SINOMED, a leading international medical device company, today announced that they have teamed up with the National University of Ireland Galway (NUI Galway) to conduct a clinical trial for a new assessment method for stenting. The trial will employ the newly patented, HT Supreme® Healing-Targeted Drug-Eluting Stent (DES), […]
TIANJIN, China, Nov. 17, 2020 /PRNewswire/ — SINOMED® today announced that Prof. Alexandra Lansky from the Yale School of Medicine, USA, presented data from its first inter-continental PIONEER III study comparing the safety and efficacy of the Supreme HT (Healing-Targeted) Drug-Eluting Stent, to the Xience or Promus Durable Polymer Drug-Eluting Stent (DP DES). One-year results, revealed […]
TIANJIN, China, July 13, 2020 /PRNewswire/ — SINOMED, a developer of innovative neuro- and cardiovascular technologies, announced the completion of the 1-year follow-up in the PIONEER-III, randomized global trial evaluating the BuMA Supreme Drug-Eluting Coronary Stent (DES). Once completed, the company plans to submit the data to the U.S. Food and Drug […]
TIANJIN, China, July 6, 2020 /PRNewswire/ — SINOMED, a developer of innovative neuro- and cardiovascular technologies, announced the completion of the 1-year follow-up in the PIONEER-III, randomized global trial evaluating the BuMA Supreme Drug-Eluting Coronary Stent (DES). Once completed, the company plans to submit the data to the U.S. Food and Drug Administration and Japanese Pharmaceuticals […]
TIANJIN, China, July 23, 2019 /PRNewswire/ — In a significant milestone toward obtaining key regulatory approvals for the BuMA Supreme Drug-Eluting Stent (DES) System, SINOMED has completed enrollment in the PIONEER III randomized, controlled clinical trial. The PIONEER III trial is designed to assess the safety and effectiveness of the BuMA Supreme […]
